Abstract
Oral drug treatment for PE has been available since 1932 when Bernard Schapiro developed Präjaculin for the treatment of lifelong PE, which was even more than a decade before the first review article on PE was published by Schapiro in 1943 and long before behavioral treatments were advocated as the first choice of treatment. However, it was only after the introduction of the selective serotonin reuptake inhibitors (SSRIs) in the early 1990s that drug treatment of PE became revolutionized. Lack of an operationalized definition of PE and the absence of an objective measure of the ejaculation time hampered a truly scientific approach to investigate the efficacy of drugs in delaying ejaculation. Waldinger et al. introduced in 1994 the intravaginal ejaculation latency time (IELT) as a standardized measure of the ejaculation time. Various drugs are currently available for the treatment of PE, but all of them, except dapoxetine, are off-label. This chapter will discuss current treatments of PE with their advantages and disadvantages including daily treatment with SSRIs, on-demand treatment with oral drugs and topical anesthetics, and psychosocial treatments.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Schapiro B. Präjaculin. In: Kombiniertes Epiphysen-Präparat gegen Reizzustände am Genitale und Hypererotismus. Hamburg: Chemische Farbrik Promonta G.m.b.H; 1932.
Schapiro B. Premature ejaculation, a review of 1130 cases. J Urol. 1943;50:374–9.
Waldinger MD. Commentary: underlying principles in ejaculatory and orgasmic function and dysfunction in the male. In: Lipshultz LI, Pastuszak AW, Goldstein AT, Giraldi A, Perelman MA, editors. Management of sexual dysfunction in men and women: an interdisciplinary approach. New York: Springer Science + Business Media; 2016. p. 133–37.
Waldinger MD. The neurobiological approach to premature ejaculation. J Urol. 2002;168:2359–67.
Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 1994;151:1377–9.
Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. An empirical operationalization study of DSM-IV diagnostic criteria for premature ejaculation. Int J Psychiatry Clin Pract. 1998;2:287–93.
Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy. J Sex Med. 2008;5:492–9.
Waldinger MD, Zwinderman AH, Schweitzer DH, et al. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res. 2004;16:369–81.
Waldinger MD. Pharmacotherapy for premature ejaculation. Expert Opin Pharmacother. 2015;16:2615–24.
Pryor JL, Althof SE, SteidLE C, et al. Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006;368(9539):929–37.
Waldinger MD. The pathophysiology of lifelong premature ejaculation. Transl Androl Urol. 2016;5:424–33.
Waldinger MD. Premature ejaculation: definition and drug treatment. Drugs. 2007;67:547–68.
Althof SE, McMahon CG, Waldinger MD, Serefoglu EC, Shindel AW, Adaikan PG, Becher E, Dean J, Giuliano F, Hellstrom WJ, Giraldi A, Glina S, Incrocci L, Jannini E, McCabe M, Parish S, Rowland D, Segraves RT, Sharlip I, Torres LO. An update of the international society of sexual medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med. 2014 Jun;2(2):60–90.
Ditto KE. SSRI discontinuation syndrome; awareness as an approach to prevention. Postgrad Med. 2003;114:79–84.
Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2003;25:255–61.
Weinrieb RM, Auriacombe M, Lynch KG, Lewis JD. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf. 2005;4:337–44.
Ahmad S. Paroxetine-induced priapism. Arch Intern Med. 1995;155:645.
Rand EH. Priapism in a patient taking sertraline. J Clin Psychiatry. 1998;59:538.
Koyuncu HH, Serefoglu EC, Yencilek E, Atalay H, Akbas N, Sarica K. Escitalopram treatment for premature ejaculation has a negative effect on semen parameters. Int J Impot Res. 2011;23:257–61.
Koyuncu H, Serefoglu EC, Ozdemir AT, Hellstrom WJ. Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation. Int J Impot Res. 2012;24:171–3.
Waldinger MD, Venema PL, van Gils AP, de Lint GJ, Schweitzer DH. Stronger evidence for small fiber sensory neuropathy in restless genital syndrome: two case reports in males. J Sex Med. 2011 Jan;8(1):325–30.
Csoka AB, Bahrick AS, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors (SSRIs). J Sex Med. 2008;5:227–33.
Waldinger MD, van Coevorden RS, Schweitzer DH, Georgiadis J. Penile anesthesia in Post SSRI Sexual Dysfunction (PSSD) responds to low-power laser irradiation: a case study and hypothesis about the role of transient receptor potential (TRP) ion channels. Eur J Pharmacol. 2015;753:263–8.
Buvat J, Tesfaye F, Rothman M, et al. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol. 2009;55:957–67.
McMahon C, Kim SW, Park NC, et al. Dapoxetine 3003 Study Investigators. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med. 2010;7(1 Pt 1):256–68.
Kaufman JM, Rosen RC, Mudumbi RV, et al. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int. 2009;103:651–8.
McMahon CG, Althof SE, Kaufman JM, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med. 2011;8:524–39.
Mirone V, Arcaniolo D, Rivas D, et al. PAUSE study team. Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: the PAUSE study. Eur Urol. 2014;65:733–9.
Xia JD, Han YF, Zhou LH, Chen Y, Dai YT. Efficacy and safety of local anaesthetics for premature ejaculation: a systematic review and meta-analysis. Asian J Androl. 2013 Jul;15(4):497–502.
Pu C, Yang L, Liu L, et al. Topical anesthetic agents for premature ejaculation: a systematic review and meta-analysis. Urology. 2013;81:799–804.
Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int. 2004;93:1018–21.
Dinsmore WW, Hackett G, Goldmeier D, et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int. 2007;99:369–75.
Dinsmore WW, Wyllie MG. PSD502 improves ejaculatory latency, control and sexualsatisfactionwhenappliedtopically 5minbeforeintercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int. 2009;103:940–9.
Carson C, Wyllie M. Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study. J Sex Med. 2010;7:3179–89.
Wu T, Yue X, Duan X, Luo D, et al. Efficacy and safety of tramadol for premature ejaculation: a systematic review and meta-analysis. Urology. 2012;80:618–24.
Yang L, Qian S, Liu H, Liu L, Pu C, Han P, Wei Q. Role of tramadol in premature ejaculation: a systematic review and meta-analysis. Urol Int. 2013;91(2):197–205.
Martyn-St James M, Cooper K, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L, Hood C. Tramadol for premature ejaculation: a systematic review and meta-analysis. BMC Urol. 2015;15(1):6.
Asimakopoulos AD, Miano R, FinazziAgrò E, et al. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis. J Sex Med. 2012;9:2404–16.
Waldinger MD, Schweitzer DH. The use of old and recent DSM definitions of premature ejaculation in observational studies: a contribution to the present debate for a new classification of PE in the DSM-V. J Sex Med. 2008;5:1079–87.
Semans JH. Premature ejaculation: a new approach. South Med J. 1956;49:353–7.
Masters WH, Johnson VE. Premature ejaculation. In: Masters WH, Johnson VE, editors. Human sexual inadequacy. Boston: Little, Brown; 1970. p. 92–115.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Waldinger, M.D. (2017). Treatment of Premature Ejaculation. In: IsHak, W. (eds) The Textbook of Clinical Sexual Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-52539-6_19
Download citation
DOI: https://doi.org/10.1007/978-3-319-52539-6_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52538-9
Online ISBN: 978-3-319-52539-6
eBook Packages: MedicineMedicine (R0)